Gene- and cell-based therapy of muscle system hereditary disorders: State-of-art by Deev R. et al.
Genes and Cells 2014 vol.9 N4, pages 6-33
Gene- and cell-based therapy of muscle system
hereditary disorders: State-of-art
Deev R., Mavlikeev M., Bozo I., Pulin A., Eremin I.
Kazan Federal University, 420008, Kremlevskaya 18, Kazan, Russia
Abstract
Genetic disorders primarily affecting skeletal muscles can be caused by dysfunction of more
than 30 genes. To date there is no effective etiotropic and pathogenetic treatment of such
disorders. Investigators focus on search for new therapeutic agents based on gene and cell
technologies, small molecules as well. There are numerous preclinical and several dozens of
clinical  studies  in  the  world.  Unfortunately  tested  technologies  did  not  lead  to  significant
advance in treatment of patients with such disorders. At the same time resulting data allow to
determine the most feasible directions of future development combining of genome correction
methods with cell delivery of corrected genome to skeletal muscles. This review is intended to
give  general  information  about  etiology  of  skeletal  muscles  genetic  disorders,  the  main
directions of biotechnological development and results of the clinical studies.
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